Publications

Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A, Chien AJ, Forero-Torres A, Ellis E, Han H, Clark A, Albain K, Boughey JC, Jaskowiak NT, Elias A, Isaacs C, Kemmer K, Helsten T, Majure M, Stringer-Reasor E, Parker C, Lee MC, Haddad T, Cohen RN, Asare S, Wilson A, Hirst GL, Singhrao R, Steeg K, Asare A, Matthews JB, Berry S, Sanil A, Schwab R, Symmans WF, van 't Veer L, Yee D, DeMichele A, Hylton NM, Melisko M, Perlmutter J, Rugo HS, Berry DA, Esserman LJ. Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. JAMA oncology. 2020. PMID: 32053137


Michelle Melisko, MD

Borno HT, Zhang S, Bakke B, Bell A, Zuniga KB, Li P, Chao K, Sabol A, Killeen T, Hong H, Walter D, Loeb S. Racial disparities and online health information: YouTube and prostate cancer clinical trials. BJU international. 2020. PMID: 32275800


Hala Borno, MD

Cham J, Zhang L, Kwek S, Paciorek A, He T, Fong G, Oh DY, Fong L. Combination immunotherapy induces distinct T-cell repertoire responses when administered to patients with different malignancies. Journal for immunotherapy of cancer. 2020. PMID: 32376721


Lawrence Fong, MD

Tempero M. Lessons From a Tiny Strand of RNA. Journal of the National Comprehensive Cancer Network : JNCCN. 2020. PMID: 32380459


Margaret Tempero, MD

Carneiro BA, Lotan TL, de Souza A, Aggarwal R. Emerging Subtypes and New Treatments for Castration-Resistant Prostate Cancer. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2020. PMID: 32479115


Rahul Aggarwal, MD

Cham J, Zhang L, Kwek S, Paciorek A, He T, Fong G, Oh DY, Fong L. Combination immunotherapy induces distinct T-cell repertoire responses when administered to patients with different malignancies. Journal for immunotherapy of cancer. 2020. PMID: 32376721


Li Zhang, PhD

Bivona TG. EGFR targeted therapy resistance: current status, challenges, and future outlook. Journal of thoracic disease. 2020. PMID: 32642197


Trever Bivona, MD, PhD

Cham J, Zhang L, Kwek S, Paciorek A, He T, Fong G, Oh DY, Fong L. Combination immunotherapy induces distinct T-cell repertoire responses when administered to patients with different malignancies. Journal for immunotherapy of cancer. 2020. PMID: 32376721


David Oh, MD, PhD

Mehta-Shah N, Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Clemens MW, Dogan A, Fisher K, Goodman AM, Goyal G, Guitart J, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Lunning MA, Mehta A, Olsen EA, Pro B, Rajguru SA, Shanbhag S, Shaver A, Shustov A, Sokol L, Torka P, Torres-Cabala C, Wilcox R, William BM, Zain J, Dwyer MA, Sundar H, Kim YH. NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020. Journal of the National Comprehensive Cancer Network : JNCCN. 2020. PMID: 32380458


Weiyun Ai, MD, PhD

Velazquez AI, McCoach CE. Tumor evolution in epidermal growth factor receptor mutated non-small cell lung cancer. Journal of thoracic disease. 2020. PMID: 32642202


Ana Velazquez Manana, MD, MSc

Gumusay O, Vitiello PP, Wabl C, Corcoran RB, Bardelli A, Rugo HS. Strategic Combinations to Prevent and Overcome Resistance to Targeted Therapies in Oncology. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2020. PMID: 32453634


Hope Rugo, MD

Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, O'Meara MJ, Rezelj VV, Guo JZ, Swaney DL, Tummino TA, Hüttenhain R, Kaake RM, Richards AL, Tutuncuoglu B, Foussard H, Batra J, Haas K, Modak M, Kim M, Haas P, Polacco BJ, Braberg H, Fabius JM, Eckhardt M, Soucheray M, Bennett MJ, Cakir M, McGregor MJ, Li Q, Meyer B, Roesch F, Vallet T, Mac Kain A, Miorin L, Moreno E, Naing ZZC, Zhou Y, Peng S, Shi Y, Zhang Z, Shen W, Kirby IT, Melnyk JE, Chorba JS, Lou K, Dai SA, Barrio-Hernandez I, Memon D, Hernandez-Armenta C, Lyu J, Mathy CJP, Perica T, Pilla KB, Ganesan SJ, Saltzberg DJ, Rakesh R, Liu X, Rosenthal SB, Calviello L, Venkataramanan S, Liboy-Lugo J, Lin Y, Huang XP, Liu Y, Wankowicz SA, Bohn M, Safari M, Ugur FS, Koh C, Savar NS, Tran QD, Shengjuler D, Fletcher SJ, O'Neal MC, Cai Y, Chang JCJ, Broadhurst DJ, Klippsten S, Sharp PP, Wenzell NA, Kuzuoglu-Ozturk D, Wang HY, Trenker R, Young JM, Cavero DA, Hiatt J, Roth TL, Rathore U, Subramanian A, Noack J, Hubert M, Stroud RM, Frankel AD, Rosenberg OS, Verba KA, Agard DA, Ott M, Emerman M, Jura N, von Zastrow M, Verdin E, Ashworth A, Schwartz O, d'Enfert C, Mukherjee S, Jacobson M, Malik HS, Fujimori DG, Ideker T, Craik CS, Floor SN, Fraser JS, Gross JD, Sali A, Roth BL, Ruggero D, Taunton J, Kortemme T, Beltrao P, Vignuzzi M, García-Sastre A, Shokat KM, Shoichet BK, Krogan NJ. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020. PMID: 32353859


Alan Ashworth, PhD

Vijayaraghavan M, King BA. Advancing Housing and Health: Promoting Smoking Cessation in Permanent Supportive Housing. Public health reports (Washington, D.C. : 1974). 2020. PMID: 32353245


Maya Vijayaraghavan, MD, MAS

Lou E, Beg S, Bergsland E, Eng C, Khorana A, Kopetz S, Lubner S, Saltz L, Shankaran V, Zafar SY. Modifying Practices in GI Oncology in the Face of COVID-19: Recommendations From Expert Oncologists on Minimizing Patient Risk. JCO oncology practice. 2020. PMID: 32352884


Emily Bergsland, MD

Merryman RW, Carreau NA, Advani RH, Spinner MA, Herrera AF, Chen R, Tomassetti S, Ramchandren R, Hamid M, Assouline S, Santiago R, Wagner-Johnston N, Paul S, Svoboda J, Bair SM, Barta SK, Liu Y, Nathan S, Karmali R, Burkart M, Torka P, David KA, Wei C, Lansigan F, Emery L, Persky D, Smith SM, Godfrey J, Chavez J, Cohen JB, Troxel AB, Diefenbach C, Armand P. Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma. The oncologist. 2020. PMID: 32275786


Michael Spinner, MD

Smith CC, Levis MJ, Frankfurt O, Pagel JM, Roboz GJ, Stone RM, Wang ES, Severson PL, West BL, Le MH, Kayser S, Lam B, Hsu HH, Zhang C, Bollag G, Perl AE. A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD-mutant acute myeloid leukemia. Blood advances. 2020. PMID: 32330242


Catherine Smith, MD

Song H, Seddighzadeh B, Cooperberg MR, Huang FW. Expression of ACE2, the SARS-CoV-2 receptor, and TMPRSS2 in prostate epithelial cells. bioRxiv : the preprint server for biology. 2020. PMID: 32510524


Franklin Huang, MD, PhD

Ricciuti B, Recondo G, Spurr LF, Li YY, Lamberti G, Venkatraman D, Umeton R, Cherniack AD, Nishino M, Sholl LM, Shapiro GI, Awad MM, Cheng ML. Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020. PMID: 32332016


Michael Cheng, MD

Huang HH, Ferguson ID, Thornton AM, Bastola P, Lam C, Lin YT, Choudhry P, Mariano MC, Marcoulis MD, Teo CF, Malato J, Phojanakong PJ, Martin TG, Wolf JL, Wong SW, Shah N, Hann B, Brooks AN, Wiita AP. Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma. Nature communications. 2020. PMID: 32321912


Thomas Martin, MD

Huang HH, Ferguson ID, Thornton AM, Bastola P, Lam C, Lin YT, Choudhry P, Mariano MC, Marcoulis MD, Teo CF, Malato J, Phojanakong PJ, Martin TG, Wolf JL, Wong SW, Shah N, Hann B, Brooks AN, Wiita AP. Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma. Nature communications. 2020. PMID: 32321912


Jeffrey Wolf, MD